Hypocretin (orexin) receptor 2

HCRTR2

Available structures

Ortholog search: PDBe RCSB

List of PDB id codes
4S0V

Identifiers

Aliases

HCRTR2, OX2R, Hypocretin (orexin) receptor 2, hypocretin receptor 2, ORXR2, OXR2

External IDs

OMIM: 602393 MGI: 2680765 HomoloGene: 1168 GeneCards: HCRTR2

Gene location (Human)

Chr.	Chromosome 6 (human)^[1]

Band	6p12.1	Start	55,106,460 bp^[1]
Band	6p12.1	End	55,282,617 bp^[1]

Gene location (Mouse)

Chr.	Chromosome 9 (mouse)^[2]

Band	9\|9 D	Start	76,133,162 bp^[2]
Band	9\|9 D	End	76,231,138 bp^[2]

RNA expression pattern

Bgee

Human

Mouse (ortholog)

Top expressed in

prefrontal cortex

pons

hypothalamus

Achilles tendon

Brodmann area 9

superior vestibular nucleus

ganglionic eminence

cingulate gyrus

placenta

substantia nigra

Top expressed in

morula

spinal ganglia

pontine nuclei

neural tube

superior frontal gyrus

cerebellar cortex

mesencephalon

hippocampus proper

hypothalamus

blastocyst

More reference expression data

BioGPS


More reference expression data

Gene ontology
Molecular function	peptide hormone binding peptide binding G protein-coupled receptor activity signal transducer activity neuropeptide receptor activity orexin receptor activity
Cellular component	integral component of membrane plasma membrane membrane integral component of plasma membrane
Biological process	phospholipase C-activating G protein-coupled receptor signaling pathway cellular response to hormone stimulus regulation of circadian sleep/wake cycle, sleep circadian sleep/wake cycle process signal transduction response to peptide chemical synaptic transmission regulation of cytosolic calcium ion concentration regulation of circadian sleep/wake cycle, wakefulness neuropeptide signaling pathway feeding behavior G protein-coupled receptor signaling pathway
Sources:Amigo / QuickGO

Orthologs

Species

Human

Mouse

Entrez


3062


387285

Ensembl


ENSG00000137252


ENSMUSG00000032360

UniProt


O43614


P58308

RefSeq (mRNA)


NM_001526 NM_001384272


NM_198962 NM_001364551

RefSeq (protein)


NP_001517


NP_945200 NP_001351480

Location (UCSC)

Chr 6: 55.11 – 55.28 Mb

Chr 9: 76.13 – 76.23 Mb

PubMed search

^[3]

^[4]

Wikidata

View/Edit Human

View/Edit Mouse

Orexin receptor type 2

Identifiers

Symbol

Orexin_rec2

Available protein structures:
Pfam	structures / ECOD
PDB	RCSB PDB; PDBe; PDBj
PDBsum	structure summary

Orexin receptor type 2 (Ox2R or OX₂), also known as hypocretin receptor type 2 (HcrtR2), is a protein that in humans is encoded by the HCRTR2 gene.^[5]

YouTube Encyclopedic

1/5
Views:
11 542
1 743
847
1 125
2 525

Transcription

Structure

The structure of the receptor has been solved to 2.5 Å resolution as a fusion protein bound to suvorexant using lipid-mediated crystallization.^[6]

Function

OX₂ is a G-protein coupled receptor expressed exclusively in the brain. It has 64% identity with OX₁. OX₂ binds both orexin A and orexin B neuropeptides. OX₂ is involved in the central feedback mechanism that regulates feeding behaviour.^[5] Mice with enhanced OX₂ signaling are resistant to high-fat diet-induced obesity.^[7]

This receptor is activated by Hipocretin, which is a wake-promoting hypothalamic neuropeptide that acts as a critical regulator of sleep in animals as Zebrafish or Mammals. This protein has mutations in Astyanax mexicanus that reduces the sleep needs of the cavefish. ^[8]

Ligands

Agonists

Danavorexton (TAK-925) – selective OX₂ receptor agonist
Firazorexton – selective OX₂ receptor agonist^[9]^[10]
Orexins – dual OX₁ and OX₂ receptor agonists
- Orexin-A – approximately equipotent at the OX₁ and OX₂ receptors^[11]^[12]
- Orexin-B – approximately 5- to 10-fold selectivity for the OX₂ receptor over the OX₁ receptor^[11]^[12]
SB-668875 – selective OX₂ receptor agonist
Suntinorexton – selective OX₂ receptor agonist^[9]^[10]
TAK-861 – selective OX₂ receptor agonist^[13]

Antagonists

Almorexant - Dual OX₁ and OX₂ antagonist
Daridorexant (nemorexant) - Dual OX₁ and OX₂ antagonist
EMPA - Selective OX₂ antagonist
Filorexant - Dual OX₁ and OX₂ antagonist
JNJ-10397049 (600x selective for OX₂ over OX₁)^[14]
Lemborexant - Dual OX₁ and OX₂ antagonist
MK-1064 - Selective OX₂ antagonist^[15]
MK-8133 - Selective OX₂ antagonist^[16]
SB-649,868 - Dual OX₁ and OX₂ antagonist
Seltorexant - Selective OX₂ antagonist
Suvorexant - Dual OX₁ and OX₂ antagonist
TCS-OX2-29 - Selective OX₂ antagonist
(3,4-dimethoxyphenoxy)alkylamino acetamides^[17]
Compound 1m - Selective OX₂ antagonist^[18]

References

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000137252 - Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000032360 - Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ ^a ^b "Entrez Gene: HCRTR2 hypocretin (orexin) receptor 2".
^ Liszewski K (1 October 2015). "Dissecting the Structure of Membrane Proteins". Genetic Engineering & Biotechnology News. 35 (17): 16. doi:10.1089/gen.35.07.09.
^ Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, et al. (January 2009). "Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity". Cell Metabolism. 9 (1): 64–76. doi:10.1016/j.cmet.2008.10.010. PMC 2630400. PMID 19117547.
^ Warren WC, Boggs TE, Borowsky R, Carlson BM, Ferrufino E, Gross JB, et al. (March 2021). "A chromosome-level genome of Astyanax mexicanus surface fish for comparing population-specific genetic differences contributing to trait evolution". Nature Communications. 12 (1): 1447. Bibcode:2021NatCo..12.1447W. doi:10.1038/s41467-021-21733-z. PMC 7933363. PMID 33664263.
^ ^a ^b "WHO Drug Information, Vol. 34, No. 2, 2020 Proposed INN: List 123 263 : International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). Who.int. Retrieved 2021-11-30.
^ ^a ^b WO application 2019027058, Kajita, Yuichi; Mikami, Satoshi & Miyanohana, Yuhei et al., "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company
^ ^a ^b Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, et al. (September 1999). "Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR". British Journal of Pharmacology. 128 (1): 1–3. doi:10.1038/sj.bjp.0702780. PMC 1571615. PMID 10498827.
^ ^a ^b Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ (January 2004). "Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor". British Journal of Pharmacology. 141 (2): 340–346. doi:10.1038/sj.bjp.0705610. PMC 1574197. PMID 14691055.
^ "Wave 1 Pipeline Market Opportunity Conference Call" (PDF). Takeda Pharmaceutical Company Limited. 8 December 2020. Archived from the original (PDF) on 2021-10-20. TAK-861, a second oral OX2R agonist will begin clinical testing in 2H FY20
^ McAtee LC, Sutton SW, Rudolph DA, Li X, Aluisio LE, Phuong VK, et al. (August 2004). "Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists". Bioorganic & Medicinal Chemistry Letters. 14 (16): 4225–4229. doi:10.1016/j.bmcl.2004.06.032. PMID 15261275.
^ Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, et al. (February 2014). "Discovery of 5-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia". ChemMedChem. 9 (2): 311–322. doi:10.1002/cmdc.201300447. PMID 24376006. S2CID 26114114.
^ Kuduk SD, Skudlarek JW, DiMarco CN, Bruno JG, Pausch MH, O'Brien JA, et al. (June 2015). "Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties". Bioorganic & Medicinal Chemistry Letters. 25 (12): 2488–2492. doi:10.1016/j.bmcl.2015.04.066. PMID 25981685.
^ Cole AG, Stroke IL, Qin LY, Hussain Z, Simhadri S, Brescia MR, et al. (October 2008). "Synthesis of (3,4-dimethoxyphenoxy)alkylamino acetamides as orexin-2 receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 18 (20): 5420–5423. doi:10.1016/j.bmcl.2008.09.038. PMID 18815029.
^ Fujimoto T, Kunitomo J, Tomata Y, Nishiyama K, Nakashima M, Hirozane M, et al. (November 2011). "Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 21 (21): 6414–6416. doi:10.1016/j.bmcl.2011.08.093. PMID 21917455.

Flier JS, Maratos-Flier E (February 1998). "Obesity and the hypothalamus: novel peptides for new pathways". Cell. 92 (4): 437–440. doi:10.1016/S0092-8674(00)80937-X. PMID 9491885. S2CID 14768585.
Willie JT, Chemelli RM, Sinton CM, Yanagisawa M (2001). "To eat or to sleep? Orexin in the regulation of feeding and wakefulness". Annual Review of Neuroscience. 24: 429–458. doi:10.1146/annurev.neuro.24.1.429. PMID 11283317.
Hungs M, Mignot E (May 2001). "Hypocretin/orexin, sleep and narcolepsy". BioEssays. 23 (5): 397–408. doi:10.1002/bies.1058. PMID 11340621. S2CID 541650.
de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. (January 1998). "The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity". Proceedings of the National Academy of Sciences of the United States of America. 95 (1): 322–327. Bibcode:1998PNAS...95..322D. doi:10.1073/pnas.95.1.322. PMC 18213. PMID 9419374.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. (February 1998). "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior". Cell. 92 (4): 573–585. doi:10.1016/S0092-8674(00)80949-6. PMID 9491897. S2CID 16294729.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. (March 1998). "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior". Cell. 92 (5): 1 page following 696. doi:10.1016/S0092-8674(02)09256-5. PMID 9527442.
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. (September 2000). "A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains". Nature Medicine. 6 (9): 991–997. doi:10.1038/79690. PMID 10973318. S2CID 18076282.
Wright GJ, Puklavec MJ, Willis AC, Hoek RM, Sedgwick JD, Brown MH, et al. (August 2000). "Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function". Immunity. 13 (2): 233–242. doi:10.1016/S1074-7613(00)00023-6. PMID 10981966.
Hartley JL, Temple GF, Brasch MA (November 2000). "DNA cloning using in vitro site-specific recombination". Genome Research. 10 (11): 1788–1795. doi:10.1101/gr.143000. PMC 310948. PMID 11076863.
Mazzocchi G, Malendowicz LK, Gottardo L, Aragona F, Nussdorfer GG (February 2001). "Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade". The Journal of Clinical Endocrinology and Metabolism. 86 (2): 778–782. doi:10.1210/jcem.86.2.7233. PMID 11158046.
Blanco M, López M, García-Caballero T, Gallego R, Vázquez-Boquete A, Morel G, et al. (April 2001). "Cellular localization of orexin receptors in human pituitary". The Journal of Clinical Endocrinology and Metabolism. 86 (4): 1616–1619. doi:10.1210/jcem.86.7.7433. PMID 11297593.
Blanco M, López M, GarcIa-Caballero T, Gallego R, Morel G, SeñarIs R, et al. (July 2001). "Cellular localization of orexin receptors in human pituitary". The Journal of Clinical Endocrinology and Metabolism. 86 (7): 1616–1619. doi:10.1210/jcem.86.7.7433. PMID 11443222.
Karteris E, Randeva HS, Grammatopoulos DK, Jaffe RB, Hillhouse EW (September 2001). "Expression and coupling characteristics of the CRH and orexin type 2 receptors in human fetal adrenals". The Journal of Clinical Endocrinology and Metabolism. 86 (9): 4512–4519. doi:10.1210/jcem.86.9.7849. PMID 11549701.
Randeva HS, Karteris E, Grammatopoulos D, Hillhouse EW (October 2001). "Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis". The Journal of Clinical Endocrinology and Metabolism. 86 (10): 4808–4813. doi:10.1210/jcem.86.10.7921. PMID 11600545.
Olafsdóttir BR, Rye DB, Scammell TE, Matheson JK, Stefánsson K, Gulcher JR (November 2001). "Polymorphisms in hypocretin/orexin pathway genes and narcolepsy". Neurology. 57 (10): 1896–1899. doi:10.1212/wnl.57.10.1896. PMID 11723285. S2CID 38597998.
Blanco M, García-Caballero T, Fraga M, Gallego R, Cuevas J, Forteza J, et al. (March 2002). "Cellular localization of orexin receptors in human adrenal gland, adrenocortical adenomas and pheochromocytomas". Regulatory Peptides. 104 (1–3): 161–165. doi:10.1016/S0167-0115(01)00359-7. PMID 11830291. S2CID 30238394.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Cell surface receptor: G protein-coupled receptors

Class A: Rhodopsin-like

Neurotransmitter

Adrenergic	α1 (A B D) α2 (A B C) β1 β2 β3
Purinergic	Adenosine (A1 A2A A2B A3) P2Y (1 2 4 5 6 8 9 10 11 12 13 14)
Serotonin	(all but 5-HT3) 5-HT1 (A B D E F) 5-HT2 (A B C) 5-HT (4 5A 6 7)
Other	Acetylcholine (M1 M2 M3 M4 M5) Dopamine D1 D2 D3 D4 D5 GHB receptor Histamine H1 H2 H3 H4 Melatonin (1A 1B 1C) TAAR (1 2 5 6 8 9)

Metabolites and
signaling molecules

Eicosanoid	CysLT (1 2) LTB4 1 2 FPRL1 OXE Prostaglandin DP (1 2), EP (1 2 3 4), FP Prostacyclin Thromboxane
Other	Bile acid Cannabinoid (CB1 CB2, GPR (18 55 119)) EBI2 Estrogen Free fatty acid (1 2 3 4) Hydroxycarboxylic acids 1 2 3 Lysophosphatidic acid (1 2 3 4 5 6) Lysophospholipid (1 2 3 4 5 6 7 8) Oxoglutarate PAF Sphingosine-1-phosphate (1 2 3 4 5) Succinate

Peptide

Neuropeptide

B/W (1
2)
FF (1
2)
S
Y (1
2
4
5)
Neuromedin (B
U (1
2))
Neurotensin (1
2)

Other

Anaphylatoxin (C3a
C5a (1
2))
Angiotensin (1
2)
Apelin
Bombesin
- BRS3
- GRPR
- NMBR)
- Bradykinin (B1
- B2)
Chemokine
Cholecystokinin (A
B)
Endothelin
- A
- B
Formyl peptide (1
2
3)
FSH
Galanin (1
2
3)
Gonadotropin-releasing hormone (1
2)
Ghrelin
Kisspeptin
Luteinizing hormone/choriogonadotropin
MAS (1
1L
D
E
F
G
X1
X2
X3
X4)
Melanocortin (1
2
3
4
5)
MCHR (1
2)
Motilin
Opioid (Delta
Kappa
Mu
Nociceptin & Zeta, but not Sigma)
Orexin (1
2)
Oxytocin
Prokineticin (1
2)
Prolactin-releasing peptide
Relaxin (1
2
3
4)
Somatostatin (1
2
3
4
5)
Tachykinin (1
2
3)
Thyrotropin
Thyrotropin-releasing hormone
Urotensin-II
Vasopressin (1A
1B
2)

Miscellaneous

Taste, bitter	TAS2R 1 3 4 5 7 8 9 10 13 14 16 19 20 30 31 38 39 40 41 42 43 45 46 50 60 Vomeronasal receptor type 1
Orphan	GPR (1 3 4 6 12 15 17 18 19 20 21 22 23 25 26 27 31 32 33 34 35 37 39 42 44 45 50 52 55 61 62 63 65 68 75 78 81 82 83 84 85 87 88 92 101 103 109A 109B 119 120 132 135 137B 139 141 142 146 148 149 150 151 152 153 160 161 162 171 173 174 176 177 182 183)
Other	Adrenomedullin Olfactory Opsin (3 4 5 1LW 1MW 1SW RGR RRH) Protease-activated (1 2 3 4) SREB (1 2 3)

Class B: Secretin-like

Adhesion	ADGRB Brain-specific angiogenesis inhibitor 1 2 3 ADGRC Cadherin 1 2 3 ADGRE EMR 1 2 3 CD97 ADGRG 1 2 3 4 5 6 7 ADGRL Latrophilin 1 2 3 ELTD1
Orphan	GPR (56 64 97 98 110 111 112 113 114 115 116 123 124 125 126 128 133 143 144 155 157)
Other	Calcitonin CALCRL Corticotropin-releasing hormone (1 2) Glucagon (GR GIPR GLP1R GLP2R) Growth-hormone-releasing hormone PACAPR1 GPR Methuselah-like proteins Parathyroid hormone (1 2) Secretin Vasoactive intestinal peptide (1 2)

Class C: Metabotropic glutamate / pheromone

Taste, sweet	TAS1R 1 2 3 Vomeronasal receptor, type 2
Other	Calcium-sensing receptor GABA_B (1 2) Glutamate receptor (Metabotropic glutamate (1 2 3 4 5 6 7 8)) GPRC6A GPR (156 158 179) RAIG (1 2 3 4)

Class F: Frizzled & Smoothened

Frizzled	Frizzled (1 2 3 4 5 6 7 8 9 10)
Smoothened	Smoothened

v t e Orexin receptor modulators
OX₁	Agonists: Orexin (A, B) Antagonists: ACT-335827 ACT-462206 ACT-539313 Almorexant AZD-4041 C4X-3256 (INDV-2000) CR-5542 Daridorexant Filorexant GSK-649868 (SB-649868) JNJ-61393215 Lemborexant RTIOX-276 SB-334867 SB-408124 Suvorexant TCS-1102 Vornorexant (ORN-0829, TS-142) YZJ-1139
OX₂	Agonists: Danavorexton (TAK-925) Firazorexton Orexin (A, B) SB-668875 Suntinorexton TAK-861 TAK-994 Antagonists: ACT-335827 ACT-462206 Almorexant Daridorexant EMPA Filorexant GSK-649868 (SB-649868) JNJ-10397049 Lemborexant MK-1064 MK-3697 MK-8133 Seltorexant Suvorexant TCS-1102 TCS-OX2-29 Vornorexant (ORN-0829, TS-142) YZJ-1139

This page was last edited on 2 April 2024, at 17:01

From Wikipedia, the free encyclopedia